Understanding how UV radiation affects immune response and skin cancer development
Role of Trem1 in ultraviolet radiation-induced immune suppression
This study is looking at how UVB rays from the sun can weaken our immune system and lead to skin cancer, and it’s testing whether blocking a specific receptor called Trem1 can help protect against this damage, using both mice and human skin samples to find better ways to prevent and treat skin cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11091999 on NIH RePORTER |
What this research studies
This research investigates the impact of ultraviolet B (UVB) radiation on the immune system and its role in skin cancer development. It focuses on a specific receptor, Trem1, which is increased in response to UVB exposure and may contribute to immune suppression. The study aims to explore how blocking Trem1 can prevent UVB-induced immune suppression and skin cancer. By using both mouse models and human skin tissues, the research seeks to develop new strategies for prevention and treatment of skin cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a history of skin cancer or those who are immunosuppressed, such as organ transplant recipients.
Not a fit: Patients who do not have a history of skin cancer or are not immunosuppressed may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new preventive measures and treatments for skin cancer, particularly for individuals at high risk due to immune suppression.
How similar studies have performed: Previous research has shown promising results in targeting immune suppression in cancer, indicating potential for success in this novel approach.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Yusuf, Nabiha — University of Alabama at Birmingham
- Study coordinator: Yusuf, Nabiha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.